Inhibrx Interest Expense 2011-2026 | INBX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Inhibrx

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-580 K	1 K	14 K	-2 K	-53 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
14 K	-580 K	-124 K

Quarterly Interest Expense Inhibrx

2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-59 K	-135 K	-217 K	-70 K	-	18 K	17 K	37 K	-	-1 K	5 K	16 K	-	-	-5 K	10 K	-	-70 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
37 K	-217 K	-34.9 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.14	0.32 %	$ 653 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 35.15	2.03 %	$ 946 M	USA
Forte Biosciences FBRX	-396 K	$ 21.07	3.73 %	$ 273 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	14.2 M	$ 90.42	0.07 %	$ 21.9 B	Germany
Autolus Therapeutics plc AUTL	36.7 M	$ 1.65	1.81 %	$ 439 M	Britain
Heron Therapeutics HRTX	1.34 M	$ 0.86	1.44 %	$ 143 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Incyte Corporation INCY	25.1 M	$ 96.77	-0.32 %	$ 18.9 B	USA
Compugen Ltd. CGEN	281 K	$ 2.6	-4.07 %	$ 243 M	Israel
Ionis Pharmaceuticals IONS	17.3 M	$ 75.11	0.07 %	$ 12 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.29	-0.98 %	$ 5.42 M	Israel
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	9 M	$ 1.54	1.99 %	$ 180 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 20.65	0.85 %	$ 2.63 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA